Gilead ponders Sovaldi price break

Share this article:

Antiviral drugmaker Gilead is rumored to be in price negotiations in India for its new hep. C pill Sovaldi (sofosbuvir). The Hindu Business Line reports that the biotech is looking to introduce Sovaldi into India's marketplace.

Twelve weeks of the treatment costs $84,000 in the US, but the framework for a deal in India is far different: the company is said to be looking to price its locally produced version of the medication at around $2,000 for six months of therapy. The company is in talks with patient advocacy groups.

Share this article:
You must be a registered member of MMM to post a comment.

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.